Epidemiological data support the hypothesis that ovarian cancers may be an endocrine-related tumor. However, the role hormone regulated genes in ovarian carcinogenesis has not been extensively studied. SPARC, also termed osteonectin, BM-40, and 43K protein, is an acidic, cysteine-rich component of the extracellular matrix that displays a high degree of interspecies sequence conservation and has been shown to be directly regulated by progesterone and dexamethasone and indirectly by cytokines. The experiments outlined in this proposal will test the hypothesis that this progesterone regulated glycoprotein SPARC is a physiologic regulator of ovarian surface epithelial cell function and deregulation of SPARC plays a role in ovarian carcinogenesis. We have cloned the SPARC gene from the normal ovarian epithelial cells and demonstrated that it is expressed at high levels in the human normal ovarian surface epithelial (HOSE) cells and at much lower levels in ovarian carcinoma cells in vitro and in vivo. Our data show that there is a tight correlation between SPARC expression in normal and neoplastic cell in vitro and in vivo and suggest that SPARC may play an important role in ovarian epithelial cell growth and differentiation. Based on these preliminary data, we propose (I). To study the expression pattern of the SPARC gene in normal ovary and ovarian tumor tissues of different stages and histological grades by Northern and Western blot analysis, in-situ hybridization and immunohistochemical detection: (2). To quantify the amount of biological active SPARC secreted by normal HOSE cells and the ovarian carcinoma cells by cell spreading assay and Northern and Western Blot analysis: and to characterize the biological effects of SPARC on these cells by [3H]-thymidine incorporation study and basement membrane invasion assay; and (3). To genetically alter SPARC expression in normal HOSE cells and ovarian carcinoma cells by transfection of full length anti-sense and sense SPARC cDNA in expression vector in order to test the hypothesis that expression of SPARC in ovarian carcinoma cells alters malignant properties such as tumor growth and invasion in vitro and in vivo . If SPARC is identified as an important regulator of ovarian epithelial cell function and up-regulation of the protein in ovarian carcinoma cells can inhibit their growth, this may suggest that strategies based on alteration in SPARC expression may have therapeutic potential in ovarian malignancies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA069453-02
Application #
2700655
Study Section
Reproductive Endocrinology Study Section (REN)
Program Officer
Mohla, Suresh
Project Start
1997-05-01
Project End
2000-04-30
Budget Start
1998-05-15
Budget End
1999-04-30
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02115
Yiu, G K; Chan, W Y; Ng, S W et al. (2001) SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 159:609-22
Garrett, A P; Ng, S W; Muto, M G et al. (2000) ras gene activation and infrequent mutation in papillary serous carcinoma of the peritoneum. Gynecol Oncol 77:105-11
Ng, S W; Yiu, G K; Liu, Y et al. (2000) Analysis of p73 in human borderline and invasive ovarian tumor. Oncogene 19:1885-90
Chan, W Y; Cheung, K K; Schorge, J O et al. (2000) Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol 156:409-17
Huang, L W; Garrett, A P; Bell, D A et al. (2000) Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol 77:369-76
Schorge, J O; Muto, M G; Lee, S J et al. (2000) BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis. Cancer Res 60:1361-4
Schorge, J O; Miller, Y B; Qi, L J et al. (2000) Genetic alterations of the WT1 gene in papillary serous carcinoma of the peritoneum. Gynecol Oncol 76:369-72
Huang, L W; Garrett, A P; Muto, M G et al. (2000) Identification of a novel 9 cM deletion unit on chromosome 6q23-24 in papillary serous carcinoma of the peritoneum. Hum Pathol 31:367-73
Huang, L W; Garrett, A P; Schorge, J O et al. (2000) Distinct allelic loss patterns in papillary serous carcinoma of the peritoneum. Am J Clin Pathol 114:93-9
Ng, S W; Liu, Y; Hasselblatt, K T et al. (1999) A new human topoisomerase III that interacts with SGS1 protein. Nucleic Acids Res 27:993-1000

Showing the most recent 10 out of 19 publications